GNH USA

Europe — EMA

Lacosamide Hikma

GNH USA supplies Lacosamide Hikma (Lacosamide), a sodium channel blocker for partial-onset seizures in epilepsy.

Lacosamide

Request sourcing

1
Pack/s

What is Lacosamide?

Lacosamide, the active ingredient in Lacosamide Hikma, is a sodium channel blocker presented as an injection solution for intravenous use. It treats partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamide Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Lacosamide used for?

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces the frequency of focal seizures in epilepsy patients. - Secondary generalized seizures: helps control seizures that spread from a focal origin. - Adjunct therapy in epilepsy: used together with other antiepileptic drugs to improve overall seizure control.

What are the side effects of Lacosamide?

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue Serious or Rare Side Effects: - Cardiac arrhythmia (including atrioventricular block) - Severe skin reactions such as Stevens‑Johnson syndrome - Respiratory depression

What precautions apply to Lacosamide?

Before initiating therapy, consider the following precautions: - Renal impairment: monitor renal function and adjust therapy as needed. - Cardiac conduction disorders: obtain baseline ECG and observe for arrhythmias. - Concomitant CNS depressants: watch for enhanced sedation. - Pregnancy: risk category unknown; weigh benefits against potential risks. - Known hypersensitivity: avoid use in patients with documented allergy to lacosamide. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Lacosamide interact with?

Lacosamide may interact with several medicines. Major Interactions (Avoid): - Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): increased risk of cardiac effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lacosamide plasma levels. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lacosamide exposure. - Central nervous system depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Anticoagulants (e.g., warfarin): may require INR monitoring.

Frequently asked questions

What is Lacosamide Hikma used for?+
Lacosamide Hikma is an intravenous antiepileptic medication indicated for the treatment of partial‑onset seizures, with or without secondary generalisation, in patients diagnosed with epilepsy. It is used as monotherapy or as an adjunct to other antiepileptic drugs to improve seizure control.
How does lacosamide work?+
Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This action stabilises hyper‑excitable neurons, reduces repetitive firing, and limits the spread of epileptic activity without markedly affecting normal neuronal conduction.
What is the usual dose of Lacosamide Hikma?+
The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s clinical condition, age, renal function and concomitant therapies. Dosing recommendations are provided in the product’s prescribing information and should be followed exactly as directed by a qualified health professional.
Is Lacosamide Hikma safe during pregnancy or breastfeeding?+
Lacosamide’s pregnancy category is listed as unknown, meaning that potential risks to the fetus have not been fully established. Use during pregnancy or lactation should only occur when the expected benefit justifies the potential risk, and it should be discussed with a healthcare provider.
How do I order Lacosamide Hikma from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.
How does Lacosamide compare with other antiepileptic drugs?+
Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, offering a different safety profile and fewer drug‑interaction concerns. It is often chosen when patients need an alternative mechanism or have intolerance to other agents.
How should Lacosamide Hikma be stored and handled?+
The product must be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Prior to administration, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration before use.
How is Lacosamide Hikma administered?+
Lacosamide Hikma is given by intravenous injection or infusion. The preparation is administered slowly over several minutes under clinical supervision, using aseptic technique. The exact infusion rate and duration are determined by the prescribing physician and documented in the treatment protocol.
What are the most serious risks associated with Lacosamide Hikma?+
The most serious adverse events include cardiac arrhythmias such as atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, and respiratory depression. Patients should be monitored for ECG changes, skin eruptions and breathing difficulties, especially during the initial dosing period.
Who should not use Lacosamide Hikma?+
Lacosamide should be avoided in individuals with known hypersensitivity to the drug or its excipients, and in patients with severe cardiac conduction disorders (e.g., advanced AV block) unless close cardiac monitoring is possible. Caution is also advised for those with significant renal impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lacosamide
Route
Intravenous Use
Manufacturer
Hikma Farmacêutica (Portugal), S.A.
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU